Myeloablative conditioning regimens for hematopoietic stem cell transplant (HSCT) are known to affect endocrine function, but little is known regarding reduced intensity conditioning (RIC) regimens. We retrospectively reviewed 114 children and young adults after single RIC HSCT. The analysis was grouped by age (o 2 and ⩾ 2 years) and diagnosis (hemophagocytic lymphohistiocystosis/Xlinked lymphoproliferative syndrome (HLH/XLP), other immune disorders, metabolic/genetic disorders). All groups displayed short stature by mean height-adjusted Z-score (HAZ) before (−1.29) and after HSCT (HAZ − 1.38, P = 0.47). After HSCT, younger children with HLH/XLP grew better (HAZ − 3.41 vs − 1.65, P = 0.006), whereas older subjects had decline in growth (HAZ − 0.8 vs − 1.01, P = 0.06). Those with steroid therapy beyond standard GVHD prophylaxis were shorter than those without (P 0.04). After HSCT, older subjects with HLH/XLP became thinner with a mean body mass index (BMI) Z-score of 1.20 vs 0.64, P = 0.02, and similar to metabolic/genetic disorders (BMI-Z = 0.59 vs − 0.99, Po 0.001). BMI increased among younger children in these same groups. Thyroid function was abnormal in 24% (18/76). 25-OH vitamin D levels were insufficient in 73% (49/65), with low bone mineral density in 8 of 19 evaluable subjects. Despite RIC, children and young adults still have significant late endocrine effects. Further research is required to compare post-transplant endocrine effects after RIC to those after standard chemotherapy protocols.
INTRODUCTION
Hematopoietic stem cell transplant (HSCT) is a potentially curative therapy for patients with many malignancies, primary immune deficiencies, metabolic diseases and inherited bone marrow failure disorders. Traditionally, stem cell transplantation has involved the use of high-dose myeloablative chemotherapy and/or radiation to facilitate successful engraftment or provide disease control in malignancy. Modern HSCT techniques with improved supportive care measures and donor matching have resulted in an increasing number of long-term survivors. Additional advances in the field of HSCT have led to novel, less intense and theoretically less toxic, reduced intensity chemotherapy (RIC) preparative regimens. Reduced intensity regimens were developed to establish donor engraftment and control of the patients' primary disease while limiting immediate and late effects to areas such as the endocrine system. Understanding the impact of preparative regimens is important for anticipating development of late effects of these treatments as our long-term survivor population continues to grow.
The endocrine system is known to be extremely susceptible to damage by preparative regimens using high-dose chemotherapy and irradiation. However, very little is known regarding the impact of RIC regimens on these late effects. 1, 2 Historically, primary hypothyroidism and primary gonadal failure are the most common endocrine outcomes due to injury from chemotherapy and radiation used before HSCT. 3 In addition, short stature and decreased bone mineral density may develop because of growth hormone (GH) deficiency or hypopituitarism. 4 Knowledge regarding endocrinologic late effects of RIC HSCT is especially lacking in the pediatric population as data are limited. Experience with late effects in adults after HSCT is not directly applicable to children, especially those who are prepubertal and still growing.
Here, we describe the effects on growth, thyroid function, vitamin D levels and bone density in pediatric patients in followup after HSCT using reduced intensity preparative regimens that are theoretically less toxic than standard regimens.
MATERIALS AND METHODS Subjects
We performed a retrospective review of HSCT patients (birth to 30 years of age) treated at Cincinnati Children's Hospital Medical Center between 1 January 2003 and 3 July 2012 to identify patients who received a reduced intensity preparative regimen without radiation. This research was performed with institutional review board approval. Patients undergoing a single HSCT and surviving at least 1 year were included. Patients were 1 grouped by diagnosis (hemophagocytic lymphohistiocystosis/X-linked lymphoproliferative syndrome (HLH/XLP), other immune disorders (primary immune deficiencies) and metabolic or genetic disorders). Clinical records were reviewed, and data abstracted. Data included patient demographics, clinical and transplant-specific data, radiologic and laboratory studies, therapeutic interventions, overall outcomes and related complications (Table 1) .
Therapy
The preparative regimen was alemtuzamab (either as a dose-escalation schedule of 3 mg, 10 mg, 15 mg, 20 mg (3 mg, 10 mg, 10 mg, 10 mg in patients o10 kg) or as a total of 1 mg/kg divided over 5 days), with timing as described previously, 5 fludarabine (150 mg/m 2 ) and melphalan (140 mg/m 2 ). GVHD prophylaxis is shown in Table 1 and was predominantly cyclosporine and steroids (1-2 mg/kg per day for up to 2 months), with or without methotrexate. Additional non-routine steroid therapy was defined as glucocorticoids administered either before HSCT or continuing beyond 2 months after HSCT. The majority of patients who received additional non-routine steroid therapy were individuals with HLH/XLP (n = 55).
Evaluation of growth and endocrine function
Height measurement (without shoes) by stadiometer was performed routinely at every outpatient assessment. Weight was measured and body mass index (kg/m 2 ) was calculated. Thyroid hormone function testing, including thyroid-stimulating hormone, thyroxine and free thyroxine levels, was performed before bone marrow transplantation. Thyroid hormone testing was also assessed 1 year following HSCT in a subset of patients (n = 77). In 64 patients, 25-OH vitamin D levels were assayed. Serum concentrations of 25-hydroxyvitamin D were determined using ultra-HPLC coupled to electrospray tandem mass spectrometry (Waters, Milford, MA, USA). 6 Bone density was assessed by dual-energy X-ray absorptiometry in 18 patients and Z-scores were corrected for height and age using an online calculator for the Bone Mineral Density in Childhood Study: http://www. bmdcspublic.com/zscore.httm.
Pubertal hormones were assessed in 8 of the 37 patients over age 12 years and complete pubertal assessments were unavailable. As such, these results were not formally analyzed for this publication.
Statistical analysis
Height-for-age Z-scores (HAZ) and body mass index Z-scores (BMI-Z) were both corrected for age. HAZ and BMI-Z were assessed using the WHO (World Health Organization) calculation for patients ⩽ 2 years at the time of transplant and the CDC calculation was used for those 42 years. Both methods rely on a transformation that is only accurate within certain ranges for height-for-age, weight-for-age and weight-for-height. Acceptable ranges for Z-scores of each are − 5 to 3, − 5 to 5 and − 4 to 5, respectively. Those patient measurements not within the range for applicable measurements were excluded from the analysis. This was carried out because the calculations of HAZ and BMI-Z are not accurate for measurements that do not satisfy these criteria, and not simply because these values are outliers.
Mean (s.e.) values were used to describe HAZ and BMI-Z throughout. Other continuous and categorical variables were reported as median (range) and frequency (percent), respectively. In total, 6 pre-BMT patients were excluded from HAZ analysis and 11 excluded from BMI-Z analysis ( Table 2) . Only one post-BMT patient was excluded from both HAZ and BMI-Z.
For change in height assessment, all patients 414 years of age at BMT were excluded, as they might have reached their adult height. Data that change with respect to time after BMT (HAZ, BMI-Z, etc) were collected on each patient at two time points, at BMT and at last follow-up. This repeated measure design induces intrasubject correlation. To account for this, a multiple linear mixed-effects model with unstructured intersubject correlation was used separately for HAZ and BMI-Z. Variables considered for inclusion into the multivariate model were age (⩽2 or 42 years), gender, additional disease-related steroid therapy pre-BMT, additional non-routine steroid therapy post BMT, diagnosis and time of measurement; all variables included an interaction with the time of measurement to assess the variables association with change in HAZ or BMI-Z. A guided backwards stepwise procedure was used to identify influential variables. Likelihood ratio tests were conducted for each variable along with its interaction with time. A variable was excluded if the likelihood ratio test yielded a P-valueo 0.05. Age, additional disease-related steroid therapy pre-BMT, BMT diagnosis and time of measurement variables were included in the model for HAZ. Age, additional disease-related steroids pre-BMT and time of measurement were included in the final BMI-Z model. P-values were found using contrast statements in SAS PROC MIXED (SAS 9.3; SAS, Cary, NC, USA). Statistical significance was assessed at the 0.05 level.
RESULTS

Patient characteristics
In a retrospective review of 772 hematopoietic stem cell transplants consecutively performed at our institution during the study period, we identified 114 individuals (16%) who underwent HSCT using a reduced intensity preparative regimen who met the study criteria. Patient demographic and transplant characteristics are shown in Table 1 . Median patient age was 5.1 years (range 0.2-27 years) and 41 were female, with a median follow-up of 4.0 years (range1-8.8 years).
Growth
All groups displayed a tendency toward short stature before (HAZ = − 1.29) and after HSCT (HAZ = − 1.38) (P = 0.47). After HSCT, Abbreviations: BMF = bone marrow failure; CSA = cyclosporine; HLH = hemophagocytic lymphohistiocystosis; MMF = mycophenolate mofetil; PID = primary immune deficiencies; RIC = reduced intensity conditioning; XLP = X-linked lymphoproliferative syndrome.
Endocrine late effects after RIC HSCT KC Myers et al younger children with HLH/XLP demonstrated improved linear growth (HAZ = − 3.41 vs − 1.65, P = 0.006), whereas older subjects showed decline in linear growth outcomes (HAZ = − 0.8 vs − 1.01, P = 0.06), although all diagnostic groups had short stature relative to normal growth in children ( Figure 1 ). Overall, subjects receiving supplemental, non-routine steroid therapy were shorter than those who did not (HAZ = − 1.43 vs − 1.20, P = 0.04). After HSCT, older subjects with HLH/XLP had decreased BMI (BMI-Z = 1.20 vs 0.64, P = 0.02), similar to metabolic or genetic disorders (BMI-Z = 0.59 vs − 0.99, P o 0.001) (Figure 2 ). There was a trend toward increased BMI-Z over time among younger children in these same groups. No differences in BMI-Z were noted in the primary immune deficiency population. Measurements are shown in Table 2 Thyroid dysfunction Thyroid function testing (thyroid-stimulating hormone, thyroxine and free thyroxine) was performed in 51 patients before HSCT. Thyroid function was normal in 42 (82%) of those patients, whereas 9 (18%) patients had primary hypothyroidism. Of those with both normal thyroid function before HSCT and post-transplant thyroid data (n = 35, 69%), 4 (11%) progressed to having primary hypothyroidism following HSCT. Unfortunately, a significant portion of patients with normal results pre-HSCT (29%) had no thyroid testing post HSCT. Five patients with abnormal thyroid testing pre-HSCT progressed to have normal thyroid testing post-HSCT; however, all were treated with thyroid hormone replacement at the time of post-HSCT measurement. In total, thyroid tests were performed in 76 subjects following HSCT, and 18 subjects (24%) had abnormal results. Eleven (14%) had evidence of primary hypothyroidism, five (7%) had central hypothyroidism and two (3%) had evidence of primary hyperthyroidism. No significant differences were noted between diagnosis groups. Vitamin D levels were insufficient (o 30 ng/mL) in 9 of 10 of these individuals who were tested. Height-adjusted Z-scores were available in 4 and ranged from 0.18 to − 1.4. Five patients had a history of avascular necrosis including the distal and/or proximal femurs in four and the foot in one. One patient required surgical correction.
DISCUSSION
Our study indicates that endocrine complications including short stature, hypothyroidism and vitamin D deficiency still occur after HSCT despite reduced intensity chemotherapy and omission of TBI. As many of these parameters may also be affected by variables such as transplant diagnosis and steroid use, our analysis was structured to address this limitation by looking at disease groups as well as steroid therapy groups. Abbreviations: BMI = body mass index; HAZ = height-for-age Z-score; HLH = hemophagocytic lymphohistiocytosis; HSCT = hematopoietic stem cell transplant; NML = normal; SCIDD = severe combined immunodeficiency; SDS = Shwachman-Diamond syndrome; Unk = unknown; XLP = X-linked lymphoproliferative disorder.
Other PID Bars represent mean and s.e. There were 102 subjects on study younger than age 14 years at the time of BMT. Six pre-BMT HAZ measurements were invalid due to CDC/WHO guidelines. Ninety-six had valid pre-BMT HAZ measurement. Six subjects were missing a post-BMT measurement and 1 was invalid. Ninety-five had a valid post-BMT HAZ measurement.
Impairment of linear growth is a well-recognized complication of HSCT. Myeloablative regimens using radiation therapy have been shown to be one of the most important elements impacting this late effect. 3, 7, 8 Impairment of linear growth may also be secondary to damage to neuroendocrine organs such as the pituitary and hypothalamus as well as direct impact on skeletal tissues, including cartilage and growth plates. Poor growth can be compounded by associated thyroid dysfunction, gonadal failure resulting in delayed puberty or prolonged steroid therapy often used after HSCT as well as underlying genetic disease effects.
The children in our cohort displayed short stature before HSCT across all disease groups. In the largest group, children with HLH/XLP, younger individuals had improved growth after HSCT while growth was slower after HSCT in older patients. Poor growth following HSCT in this older population is indeed interesting and consistent in all groups analyzed regardless of original diagnosis. These findings highlight the contrast between younger and older patients with regard to treatment effects. The etiology of this contrast may be multifactorial, but it is perhaps possible that the accumulated effects of longer courses of steroids in older patients prevent rapid growth recovery following HSCT compared with younger children. It would be most interesting to carry the results out until final adult height is achieved to highlight any eventual differences, which is the aim of future ongoing work in a larger cohort.
Overall, steroid treatment resulted in shorter stature; however, numbers were not sufficient to perform a complete analysis of the effects of steroids by diagnostic group. Many children remained short after HSCT (HAZ − 1.29 (−5.5 to 0.60) reflecting lasting effects of steroid exposure or development of hormone deficiencies even with reduced intensity chemotherapy. Measurements of GH, IGF-1 or IGF-BP3 levels were not included in routine care after HSCT, and thus our cohort cannot address the mechanism of slower growth, which may be important to evaluate in future studies.
It is unclear to what degree GH deficiency affects growth impairment after HSCT or what role GH replacement has in treatment over time. However, there are some data from the Childhood Cancer Survivor Study that treatment with GH replacement does not increase risk of relapse. 9 There remains, however, theoretical concern that GH replacement may increase risk for secondary malignancy in a population that already has a significant susceptibility to malignancy. GH replacement should be considered in patient populations with non-malignant disorders in conjunction with a pediatric endocrinologist.
Like growth disturbances, gonadal dysfunction or failure after HSCT has also been strongly associated with the use of radiation and busulfan in the preparative regimen. 7 Of note, our current patient cohort had insufficient numbers of pubertal-age children to analyze gonadal function after RIC for HSCT. However, in standard HSCT preparatory regimens, treatment with TBI or alkylating agents (such as busulfan or cyclophosphomide) may result in hypergonadotropic hypogonadism, and recovery of gonadal function is extremely rare. 7, 10 Testicular impairment is drug-specific and dose-related. The use of busulfan at 16 mg/kg and cyclophosphomide at 200 mg/kg resulted in significant testicular dysfunction in~80% of patients. 10 In contrast to females, the age and pubertal status of males at the time of HSCT does not appear to affect the occurrence of testicular dysfunction.
Degree of ovarian dysfunction is also drug-specific and doserelated. However, in females there is a significant role of age and pubertal status in determining the magnitude of damage from alkylating agents. Irreversible ovarian failure can occur in adult women receiving lower doses of both radiation and alkylating chemotherapy agents (6 Gy of radiation) compared with children and adolescents (10 Gy). The typical doses of TBI delivered during standard HSCT preparative regimens results in ovarian damage in almost all girls over 10 years of age, and in approximately half of those o 10 years.
7 Our cohort will be followed in the future for observation of their pubertal development.
Thyroid dysfunction, most commonly primary hypothyroidism, also remains an extremely common complication after HSCT, although autoimmune thyroid disorders, thyroid nodules or secondary thyroid carcinomas can also occur. Thyroid injury has been associated with the use of myeloablative conditioning regimens where radiation is both dose-and delivery-dependent. Patients receiving hyperfractionated TBI are less likely to have thyroid dysfunction (15%) compared with those receiving single dose irradiation (89%). 11, 12 However, many of our patients continued to have thyroid dysfunction, despite the absence of radiation in the conditioning regimen. In our study, 11% of patients developed new hypothyroidism following HSCT. This is similar to the rate of thyroid disease acquired within the first 3-5 years following HSCT in other studies conducted with non-RIC regimens, 13, 14 which is a novel finding and suggests similar risks for thyroid disease between RIC and non-RIC regimens.
Vitamin D deficiency is a widespread issue in the general population in the United States, with reports in the literature suggesting prevalence of 40-50% in the pediatric population. 15 In contrast, prevalence in our cohort was higher, with 73% of our patients demonstrating deficiency. Vitamin D deficiency may reflect decreased dietary intake or impaired absorption during HSCT, decreased exercise and/or sun exposure, decreased renal function or increased steroid use in our cohort. While the number of patients studied in our cohort is limited, low vitamin D concentrations may be contributing to the decreased bone mineral density by densitometry observed in a few members of our cohort. Additionally, the literature supports an important role for vitamin D in immune function, Therefore, vitamin D deficiency may potentially influence immune reconstitution, GVHD and/or survival after HSCT, and in our current practice, the levels are maintained in the normal range during and after HSCT. 16, 17 The current analysis demonstrates that endocrine complications remain a significant issue after pediatric HSCT, despite the use of reduced intensity chemotherapy regimens and avoidance of radiation. This is particularly disappointing in our cohort of patients with non-malignant disorders in whom we anticipate no further risk of disease after HSCT. Prospective follow-up is necessary for the detection of these disorders and to improve understanding of how endocrine late effects manifest in this population. Our group proposed recommendations for comprehensive post-transplant endocrine function monitoring (Table 3) . BMI-Z Figure 2 . BMI-Z before and after RIC HSCT. After HSCT, older subjects with HLH/XLP had decreased BMI (BMI-Z = 1.20 vs 0.64, P = 0.02), which was similar to metabolic or genetic disorders (BMI-Z = 0.59 vs − 0.99, P o0.001). Bars represent mean and s.e. There were 114 subjects on study. Eleven pre-BMT measurements were invalid because of CDC/WHO guidelines. Hundred and three and two had valid pre-BMT BMI-Z measurement. Twelve subjects were missing a post-BMT measurement and one was invalid. One hundred and three had a valid post-BMT HAZ measurement.
Multidisciplinary follow-up after HSCT, including the involvement of a pediatric endocrinologist, is crucial to maximize long-term outcomes. Our current practice now includes collaborative longterm follow-up in comprehensive joint HSCT and endocrine clinics. Similarly, comparison is needed of post-HSCT endocrine complications after reduced intensity vs standard myeloablative protocols. Abbreviations: ACTH = adrenocorticotropic hormone; AMH = anti-Mullerian hormone; DXA = dual-energy X-ray absorptiometry; FSH = follicle-stimulating hormone; HSCT = hematopoietic stem cell transplant; LH = luteinizing hormone; T4 = thyroxine; TSH = thyroid-stimulating hormone. Majhail et al., 18 Brennan and Shalet, 19 Sanders et al., 14 Ranke et al. 20 and Sanders. 
